共 105 条
[11]
Daly AK(2002)Clinical significance of the cytochrome P450 2C19 genetic polymorphism Clin Pharmacokinet 41 913-958
[12]
Howland RH(2012)Testing for variants in CYP2C19: population frequencies and testing experience in a clinical laboratory Genet Med 14 95-100
[13]
Dalmadi B(2006)HPLC determination of tolperisone in human plasma Arch Pharm Res 29 339-342
[14]
Leibinger J(2007)Considerable interindividual variation in the pharmacokinetics of tolperisone HCl Int J Clin Pharmacol Ther 45 110-113
[15]
Szeberenyi S(2012)Determination of tolperisone in human plasma by liquid chromatography/tandem mass spectrometry for clinical application J Chromatogr B Analyt Technol Biomed Life Sci 12 59-63
[16]
Borbas T(2012)Effect of the CYP2C19 genotype on the pharmacokinetics of icotinib in healthy male volunteers Eur J Clin Pharmacol 68 1677-1680
[17]
Farkas S(2012)CYP2C19 polymorphism affects single-dose pharmacokinetics of oral pantoprazole in healthy volunteers Eur J Clin Pharmacol 68 1267-1274
[18]
Szombathelyi Z(2009)Investigation of the influence of CYP1A2 and CYP2C19 genetic polymorphism on 2-cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]-2-butenamide (A77 1726) pharmacokinetics in leflunomide-treated patients with rheumatoid arthritis Drug Metab Dispos 37 2061-2068
[19]
Tihanyi K(2000)CYP2C19 polymorphism effect on phenobarbitone. Pharmacokinetics in Japanese patients with epilepsy: analysis by population pharmacokinetics Eur J Clin Pharmacol 55 821-825
[20]
Balint J(2008)Tolperisone—a typical representative of a class of centrally acting muscle relaxants with less sedative side effects CNS Neurosci Ther 14 107-119